Cargando…

Structure-Based Design of α-Substituted Mercaptoacetamides as Inhibitors of the Virulence Factor LasB from Pseudomonas aeruginosa

[Image: see text] Antivirulence therapy has become a widely applicable method for fighting infections caused by multidrug-resistant bacteria. Among the many virulence factors produced by the Gram-negative bacterium Pseudomonas aeruginosa, elastase (LasB) stands out as an important target as it plays...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaya, Cansu, Walter, Isabell, Alhayek, Alaa, Shafiei, Roya, Jézéquel, Gwenaëlle, Andreas, Anastasia, Konstantinović, Jelena, Schönauer, Esther, Sikandar, Asfandyar, Haupenthal, Jörg, Müller, Rolf, Brandstetter, Hans, Hartmann, Rolf W., Hirsch, Anna K.H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112332/
https://www.ncbi.nlm.nih.gov/pubmed/35451824
http://dx.doi.org/10.1021/acsinfecdis.1c00628
_version_ 1784709399507369984
author Kaya, Cansu
Walter, Isabell
Alhayek, Alaa
Shafiei, Roya
Jézéquel, Gwenaëlle
Andreas, Anastasia
Konstantinović, Jelena
Schönauer, Esther
Sikandar, Asfandyar
Haupenthal, Jörg
Müller, Rolf
Brandstetter, Hans
Hartmann, Rolf W.
Hirsch, Anna K.H.
author_facet Kaya, Cansu
Walter, Isabell
Alhayek, Alaa
Shafiei, Roya
Jézéquel, Gwenaëlle
Andreas, Anastasia
Konstantinović, Jelena
Schönauer, Esther
Sikandar, Asfandyar
Haupenthal, Jörg
Müller, Rolf
Brandstetter, Hans
Hartmann, Rolf W.
Hirsch, Anna K.H.
author_sort Kaya, Cansu
collection PubMed
description [Image: see text] Antivirulence therapy has become a widely applicable method for fighting infections caused by multidrug-resistant bacteria. Among the many virulence factors produced by the Gram-negative bacterium Pseudomonas aeruginosa, elastase (LasB) stands out as an important target as it plays a pivotal role in the invasion of the host tissue and evasion of the immune response. In this work, we explored the recently reported LasB inhibitor class of α-benzyl-N-aryl mercaptoacetamides by exploiting the crystal structure of one of the compounds. Our exploration yielded inhibitors that maintained inhibitory activity, selectivity, and increased hydrophilicity. These inhibitors were found to reduce the pathogenicity of the bacteria and to maintain the integrity of lung and skin cells in the diseased state. Furthermore, two most promising compounds increased the survival rate of Galleria mellonella larvae treated with P. aeruginosa culture supernatant.
format Online
Article
Text
id pubmed-9112332
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-91123322022-05-18 Structure-Based Design of α-Substituted Mercaptoacetamides as Inhibitors of the Virulence Factor LasB from Pseudomonas aeruginosa Kaya, Cansu Walter, Isabell Alhayek, Alaa Shafiei, Roya Jézéquel, Gwenaëlle Andreas, Anastasia Konstantinović, Jelena Schönauer, Esther Sikandar, Asfandyar Haupenthal, Jörg Müller, Rolf Brandstetter, Hans Hartmann, Rolf W. Hirsch, Anna K.H. ACS Infect Dis [Image: see text] Antivirulence therapy has become a widely applicable method for fighting infections caused by multidrug-resistant bacteria. Among the many virulence factors produced by the Gram-negative bacterium Pseudomonas aeruginosa, elastase (LasB) stands out as an important target as it plays a pivotal role in the invasion of the host tissue and evasion of the immune response. In this work, we explored the recently reported LasB inhibitor class of α-benzyl-N-aryl mercaptoacetamides by exploiting the crystal structure of one of the compounds. Our exploration yielded inhibitors that maintained inhibitory activity, selectivity, and increased hydrophilicity. These inhibitors were found to reduce the pathogenicity of the bacteria and to maintain the integrity of lung and skin cells in the diseased state. Furthermore, two most promising compounds increased the survival rate of Galleria mellonella larvae treated with P. aeruginosa culture supernatant. American Chemical Society 2022-04-22 2022-05-13 /pmc/articles/PMC9112332/ /pubmed/35451824 http://dx.doi.org/10.1021/acsinfecdis.1c00628 Text en © 2022 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by/4.0/Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Kaya, Cansu
Walter, Isabell
Alhayek, Alaa
Shafiei, Roya
Jézéquel, Gwenaëlle
Andreas, Anastasia
Konstantinović, Jelena
Schönauer, Esther
Sikandar, Asfandyar
Haupenthal, Jörg
Müller, Rolf
Brandstetter, Hans
Hartmann, Rolf W.
Hirsch, Anna K.H.
Structure-Based Design of α-Substituted Mercaptoacetamides as Inhibitors of the Virulence Factor LasB from Pseudomonas aeruginosa
title Structure-Based Design of α-Substituted Mercaptoacetamides as Inhibitors of the Virulence Factor LasB from Pseudomonas aeruginosa
title_full Structure-Based Design of α-Substituted Mercaptoacetamides as Inhibitors of the Virulence Factor LasB from Pseudomonas aeruginosa
title_fullStr Structure-Based Design of α-Substituted Mercaptoacetamides as Inhibitors of the Virulence Factor LasB from Pseudomonas aeruginosa
title_full_unstemmed Structure-Based Design of α-Substituted Mercaptoacetamides as Inhibitors of the Virulence Factor LasB from Pseudomonas aeruginosa
title_short Structure-Based Design of α-Substituted Mercaptoacetamides as Inhibitors of the Virulence Factor LasB from Pseudomonas aeruginosa
title_sort structure-based design of α-substituted mercaptoacetamides as inhibitors of the virulence factor lasb from pseudomonas aeruginosa
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112332/
https://www.ncbi.nlm.nih.gov/pubmed/35451824
http://dx.doi.org/10.1021/acsinfecdis.1c00628
work_keys_str_mv AT kayacansu structurebaseddesignofasubstitutedmercaptoacetamidesasinhibitorsofthevirulencefactorlasbfrompseudomonasaeruginosa
AT walterisabell structurebaseddesignofasubstitutedmercaptoacetamidesasinhibitorsofthevirulencefactorlasbfrompseudomonasaeruginosa
AT alhayekalaa structurebaseddesignofasubstitutedmercaptoacetamidesasinhibitorsofthevirulencefactorlasbfrompseudomonasaeruginosa
AT shafieiroya structurebaseddesignofasubstitutedmercaptoacetamidesasinhibitorsofthevirulencefactorlasbfrompseudomonasaeruginosa
AT jezequelgwenaelle structurebaseddesignofasubstitutedmercaptoacetamidesasinhibitorsofthevirulencefactorlasbfrompseudomonasaeruginosa
AT andreasanastasia structurebaseddesignofasubstitutedmercaptoacetamidesasinhibitorsofthevirulencefactorlasbfrompseudomonasaeruginosa
AT konstantinovicjelena structurebaseddesignofasubstitutedmercaptoacetamidesasinhibitorsofthevirulencefactorlasbfrompseudomonasaeruginosa
AT schonaueresther structurebaseddesignofasubstitutedmercaptoacetamidesasinhibitorsofthevirulencefactorlasbfrompseudomonasaeruginosa
AT sikandarasfandyar structurebaseddesignofasubstitutedmercaptoacetamidesasinhibitorsofthevirulencefactorlasbfrompseudomonasaeruginosa
AT haupenthaljorg structurebaseddesignofasubstitutedmercaptoacetamidesasinhibitorsofthevirulencefactorlasbfrompseudomonasaeruginosa
AT mullerrolf structurebaseddesignofasubstitutedmercaptoacetamidesasinhibitorsofthevirulencefactorlasbfrompseudomonasaeruginosa
AT brandstetterhans structurebaseddesignofasubstitutedmercaptoacetamidesasinhibitorsofthevirulencefactorlasbfrompseudomonasaeruginosa
AT hartmannrolfw structurebaseddesignofasubstitutedmercaptoacetamidesasinhibitorsofthevirulencefactorlasbfrompseudomonasaeruginosa
AT hirschannakh structurebaseddesignofasubstitutedmercaptoacetamidesasinhibitorsofthevirulencefactorlasbfrompseudomonasaeruginosa